title: Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
abstract: Veno-occlusive disease (VOD) of the liver is one of the most frequent fatal complications after bone marrow transplantation (BMT). A decrease of natural anticoagulants, in particular protein C (PC), has been assumed to be involved in the pathogenesis of the disease. We determined PC and antithrombin III (AT III) levels in two patients undergoing BMT and subsequent liver transplantation due to VOD. Additionally, in one of the patients protein S (PS) levels were also measured. Normal baseline (day-8) PC levels (86 and 89%) were markedly reduced in both patients at the time of VOD manifestation on day 20 and 40, respectively (26 and 31%). PS levels lay within the normal range from day-8 (before myeloablative chemotherapy) until one week after clinical onset of VOD when substitution therapy with fresh frozen plasma (FFP) was initiated. AT III levels decreased moderately during the second and third posttransplant week, but were normal in the patient with a late clinical manifestation of VOD. In both patients PC and PS levels lay within the normal range after liver transplantation which was performed on day 41 and 79, respectively. AT III was substituted several times. Both patients died due to infectious complications on day 141 and 101, respectively. The data confirm previous reports that a decrease of PC is observed in BMT recipients and can be associated with hepatic vein occlusion. Whereas the relevance of AT III is uncertain, PS does not seem to be involved in the pathogenesis of VOD. Liver transplantation lead to normalization of PC levels, but its significance remains to be discussed in terms of ethical justifiability, medical feasibility and costs.
authors.affiliation: Med. Klinik III, Klinikum Grosshadern, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Salat
authors.forename: E
authors.initials: E
authors.lastname: Holler
authors.forename: P
authors.initials: P
authors.lastname: Göhring
authors.forename: S
authors.initials: S
authors.lastname: Poley
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: R
authors.initials: R
authors.lastname: Pihusch
authors.forename: B
authors.initials: B
authors.lastname: Reinhardt
authors.forename: H J
authors.initials: HJ
authors.lastname: Krämling
authors.forename: M
authors.initials: M
authors.lastname: Haller
authors.forename: E
authors.initials: E
authors.lastname: Hiller
mesh_terms: D000208:Acute Disease; D000328:Adult; D000990:Antithrombin III / Q000032:analysis*; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000097:blood* / Q000209:etiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000032:analysis*; D017293:Protein S / Q000032:analysis*
chemical_list: D015415:Biomarkers; D011486:Protein C; D017293:Protein S; D000990:Antithrombin III